Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73), Briefing.com reports. The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return […]
Covestor Ltd raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 564.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 797 shares of the company’s stock after purchasing an additional 677 shares during the period. Covestor Ltd’s holdings in Apellis […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $92.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 42.97% from the company’s current price. Several […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 10,670,000 shares, a decline of 11.3% from the January 15th total of 12,030,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the days-to-cover […]